Antisense Oligonucleotides (ASOs) Products for Hypertriglyceridemia
Hypertriglyceridemia is often observed as the result of lipid abnormality frequently associated with other lipid and metabolic derangements. Antisense oligonucleotide (ASOs) are promising new agents for the treatment of hypertriglyceridemia. Currently, the antisense compounds targeting Apolipoprotein C-III (ApoC-III) and apolipoprotein(a) [(apo(a)] have been developed to be used in hypertriglyceridemia therapy. The two targets are important biomarkers of cardiovascular disease (CVD) risk. The antisense drugs work by binding to the target mRNA, blocking the translation and initiating its RNase H1-mediated degradation. Through inhibiting the synthesis of specific proteins, ASOs could be promising new agents for the treatment of hypertriglyceridemia and hyperlipoproteinemia(a), respectively.
Creative Biolabs is a world-renowned service provider for antisense oligonucleotides therapy development. We provide a series of top-quality ASO products for hypertriglyceridemia therapy. Stringent criteria are applied to implement quality control of antisense products in order to guarantee reliability. We are dedicated to providing the best-characterized antisense therapy service to help our worldwide customers. Please feel free to contact us for a quote and more information.
Reference
- Hanssen, R. and Gouni-Berthold, I. (2017). Antisense Oligonucleotides for the Treatment of Hypertriglyceridemia and Hyperlipoproteinemia(a). Current Pharmacology Reports. 3(6), pp.458-468.
